Lite Strategy (LITS) Intangibles (2012 - 2026)

Lite Strategy (LITS) posted Intangibles of $40.3 million for Q1 2026, down 36.97% on a QoQ basis from $64.0 million in Q4 2025.

Analysis

Lite Strategy (LITS) Intangibles (2012 - 2026) Analysis & Trends

Lite Strategy has reported Intangibles for 11 years, with the latest figure at $40.3 million in Q1 2026.

On a quarterly basis, Intangibles changed N/A year-over-year to $40.3 million in Q1 2026; TTM through Mar 2026 was $40.3 million, a N/A change from a year earlier, with the FY2019 full-year figure at $261000.0, down 11.82% from the prior year.
Intangibles was $40.3 million for Q1 2026 at Lite Strategy, down from $64.0 million in the prior quarter.
The five-year high for Intangibles was $99.4 million in Q3 2025, with the low at $40.3 million in Q1 2026.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Intangibles (Qtr)
1	Amgen	206.44 Bn	192.45 Bn	7.24 Bn	20.49 Bn
2	Gilead Sciences	179.97 Bn	176.79 Bn	6.22 Bn	14.03 Bn
3	Vertex Pharmaceuticals	130.57 Bn	122.72 Bn	2.84 Bn	412.80 Mn
4	Regeneron Pharmaceuticals	81.63 Bn	73.63 Bn	3.93 Bn	1.31 Bn
5	Argenx Se	60.34 Bn	55.16 Bn	1.37 Bn	266.00 Mn
6	Moderna	54.37 Bn	49.23 Bn	52.00 Mn	-
7	Alnylam Pharmaceuticals	33.07 Bn	29.76 Bn	992.69 Mn	-
8	Biogen	31.84 Bn	30.55 Bn	1.96 Bn	13.52 Bn
9	Roivant Sciences	29.49 Bn	29.49 Bn	1.16 Mn	-
10	Lite Strategy	38.03 Mn	30.49 Mn	-	40.32 Mn

Historic Data

Download Data